Aquestive(US:AQST) Globenewswire·2026-01-09 15:06Core Viewpoint - Block & Leviton is investigating Aquestive Therapeutics, Inc. for potential securities law violations following a significant drop in the company's stock price due to FDA deficiencies in its new drug application for Anaphylm [1][2]. Group 1: Company Overview - Shares of Aquestive Therapeutics fell more than 40% on January 9, 2026, after the company disclosed that the FDA identified deficiencies in its new drug application for Anaphylm, raising the risk of delayed approval [2]. - Block & Leviton is investigating the company's prior disclosures to determine if there were any securities law violations [4]. Group 2: Investor Information - Any investor who purchased Aquestive Therapeutics common stock and has experienced a decline in their investment may be eligible to recover losses, regardless of whether they have sold their shares [3]. - Investors are encouraged to contact Block & Leviton for more information on how to proceed with potential recovery [5]. Group 3: Legal Action and Whistleblower Information - Block & Leviton may file an action to recover losses on behalf of investors who have lost money due to the company's disclosures [4]. - Whistleblowers with non-public information about Aquestive Therapeutics are encouraged to assist in the investigation or report to the SEC, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors and representing many top institutional investors [7].